Home » Topics » BioWorld Science

BioWorld Science
RSS

Lilly's olanzapine deemed approvable

Sep. 6, 1996

Antipsychotic dopaminergic compounds from E. Merck

Sep. 6, 1996

Lilly discloses new serotonergic agents

Sep. 6, 1996

NS-2710 in development for anxiety

Sep. 6, 1996

Melatonergic agents from ADIR

Sep. 6, 1996

MRI contrast agent from Advanced Magnetics cleared for launch

Sep. 6, 1996

Agreement reached on tests for hepatitis C virus

Sep. 6, 1996

Assays for the diagnosis of Alzheimer's disease

Sep. 6, 1996

Retinoid compound from Sparta enters U.S. clinical trials

Sep. 6, 1996

Oral treatment for periodontitis filed for approval

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...